CAFFEINE 200 MG
CAFFEINE : 200 MG · DIN 02229824 · ADDED DIMENSIONS
Health Canada status: CANCELLED POST MARKET
What is CAFFEINE?
CAFFEINE 200 MG contains CAFFEINE : 200 MG. It is listed in the Health Canada Drug Product Database under DIN 02229824, held by ADDED DIMENSIONS, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 25-Sep-2006. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What else is CAFFEINE called?
The same molecule, CAFFEINE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Adco-Dol | Latin | South Africa |
| Dynapayne Tablets | Latin | South Africa |
| Lenadol | Latin | South Africa |
| Lenapain | Latin | South Africa |
| Pynstop | Latin | South Africa |
| Syndol | Latin | South Africa |
| Tenston SA Capsules | Latin | South Africa |
| Tenston SA Tablets | Latin | South Africa |
| Betapyn | Latin | South Africa |
| Codoxol | Latin | South Africa |
| Pharmadol | Latin | South Africa |
| Sedinol | Latin | South Africa |
| Spectrapain Forte | Latin | South Africa |
| Spectrapain Forte T | Latin | South Africa |
| ADOL EXTRA CAPLETS | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02229824 |
|---|---|
| Brand name | CAFFEINE |
| Generic / active ingredient | CAFFEINE : 200 MG |
| Manufacturer | ADDED DIMENSIONS |
| Strength | 200 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | N06BC01 CAFFEINE |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 25-Sep-2006 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02229824 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2229824 |
| Brand name | CAFFEINE |
| Active ingredient / INN | CAFFEINE : 200 MG |
| ATC code | N06BC01 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N06 |
| Health Canada schedule | NON-PRESCRIPTION DRUGS |
| Biosimilar biologic | No |
| Market authorization holder | ADDED DIMENSIONS |
Which pack is which?
| Strength on the label | 200 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Is CAFFEINE in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by OMEGA LABORATORIES LIMITED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N06BC01 CAFFEINE. 3 of 11 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CAFFEINE CITRATE INJECTION USP | 20 MG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | DIN 02526778 |
| CAFFEINE CITRATE ORAL SOLUTION USP | 20 MG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | DIN 02526751 |
| PEYONA | 20 MG | SOLUTION | CHIESI FARMACEUTICI S.P.A. | MARKETED | DIN 02496771 |
| ALERT AID CAFFEINE CAPSULES 175MG | 175 MG | CAPSULE | SUN LABS LTD | CANCELLED POST MARKET | DIN 01941089 |
| ALERT AID CAFFEINE TABLETS 175MG | 175 MG | TABLET | SUN LABS LTD | CANCELLED POST MARKET | DIN 01941100 |
| ALERT TAB 100MG | 100 MG | TABLET | NUTRIBON (1986) INC. | CANCELLED POST MARKET | DIN 01943642 |
| DESTIM - TAB 200MG | 200 MG | TABLET | D & E PHARMACEUTICALS INC. | CANCELLED POST MARKET | DIN 02130521 |
| DIURETTE WATER PILLS | 200 MG | TABLET | ALVA-AMCO PHARMACAL COMPANIES, LLC | CANCELLED PRE MARKET | DIN 02238753 |
| PHENFREE CAFFEINE 100MG CAPSULES | Strength | Capsule | UPPER 49TH IMPORTS INC. 2715 Bristol Circle, Unit #2 Oakville Ontario Canada L6H 6X5 | CANCELLED POST MARKET | DIN 02239784 |
| SUGARLOAF SPRING CAFFEINE, CAFFEINATED SPRING WATER | 50 MG | LIQUID | SUGARLOAF SPRING RAIN INTERNATIONAL LTD. | CANCELLED POST MARKET | DIN 02237490 |
Who else supplies CAFFEINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CAFFEINE appears in 35 registered pack listings across 5 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does CAFFEINE cost around the world?
CAFFEINE is listed on 6 national price registers Nexara tracks, across 105 pack listings published on 5 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| South Africa | single exit price | 41 | 83 | 01 Sep 2026 |
| Saudi Arabia | public | 9 | 12 | 01 Sep 2026 |
| United Kingdom | hospital | 5 | 5 | 31 Aug 2026 |
| United Arab Emirates | public | 2 | 2 | 31 Aug 2026 |
| Greece | producer price (ex-factory) | 2 | 2 | 03 Sep 2026 |
| United States | acquisition | 1 | 1 | 03 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.